Assignee
CSL BEHRING GMBH
DE·39 granted patents·23 pending applications·283 citations·filing 2001–2024
Top patents by PatentIndex Score
62 records- 0197US7939632B2Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2007·Granted May 10, 2011·40 cites·31 claims
- 0292US7572769B2Fibrin adhesive granulate and method for its preparationCSL BEHRING GMBH·Filed 2007·Granted Aug 11, 2009·20 cites·24 claims
- 0390US9856326B2Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodiesCSL BEHRING GMBH·Filed 2016·Granted Jan 2, 2018·9 cites·23 claims
- 0490US7491197B2Fluid transfer deviceCSL BEHRING GMBH·Filed 2004·Granted Feb 17, 2009·96 cites·42 claims
- 0588US9856325B2Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodiesCSL BEHRING GMBH·Filed 2016·Granted Jan 2, 2018·6 cites·24 claims
- 0688US7550567B2Fibrinogen purificationCSL BEHRING GMBH·Filed 2005·Granted Jun 23, 2009·21 cites·21 claims
- 0788US7351561B2Thrombin preparations and process for their productionCSL BEHRING GMBH·Filed 2001·Granted Apr 1, 2008·28 cites·6 claims
- 0886US8962802B2Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1CSL BEHRING GMBH·Filed 2013·Granted Feb 24, 2015·7 cites·14 claims
- 0983US9458223B2Von willebrand factor variants having improved factor VIII binding affinityCSL BEHRING GMBH·Filed 2013·Granted Oct 4, 2016·8 cites·20 claims
- 1082US9987328B2Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfacesCSL BEHRING GMBH·Filed 2016·Granted Jun 5, 2018·4 cites·20 claims
- 1182US8653245B2Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1CSL BEHRING GMBH·Filed 2013·Granted Feb 18, 2014·4 cites·12 claims
- 1281US7335634B2Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimersCSL BEHRING GMBH·Filed 2005·Granted Feb 26, 2008·12 cites·22 claims
- 1376US10513560B2Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodiesCSL BEHRING GMBH·Filed 2017·Granted Dec 24, 2019·1 cites·21 claims
- 1476US8012728B2Thrombin preparations and process for their productionCSL BEHRING GMBH·Filed 2006·Granted Sep 6, 2011·2 cites·10 claims
- 1576US2024398914A1Combination therapy using a factor xii inhibitor and a c-1 inhibitorCSL BEHRING GMBH·Filed 2024·Application pending·0 cites
- 1675US7939288B2Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniquesCSL BEHRING GMBH·Filed 2006·Granted May 10, 2011·7 cites·34 claims
- 1772US9598461B2Method of purifying therapeutic proteinsCSL BEHRING GMBH·Filed 2014·Granted Mar 21, 2017·1 cites·28 claims
- 1872US8051884B2Device for combining components by means of negative pressure under sterile conditionsCSL BEHRING GMBH·Filed 2007·Granted Nov 8, 2011·6 cites·11 claims
- 1970US7625866B2Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating theretoCSL BEHRING GMBH·Filed 2003·Granted Dec 1, 2009·6 cites·11 claims
- 2069US9957329B2Factor XII inhibitors for the treatment of neurological inflammatory disordersCSL BEHRING GMBH·Filed 2013·Granted May 1, 2018·3 cites·14 claims
- 2169US7892842B2Procedure for the determination of the activity of the protease which activates factor VII from protein solutionsCSL BEHRING GMBH·Filed 2008·Granted Feb 22, 2011·0 cites·19 claims
- 2268US2021283530A1Method of purifying therapeutic proteinsCSL BEHRING GMBH·Filed 2021·Application pending·0 cites
- 2367US11345759B2Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodiesCSL BEHRING GMBH·Filed 2019·Granted May 31, 2022·0 cites·22 claims
- 2467US2020095567A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 2567US2020129600A1Combination therapy using a factor xii inhibitor and a c-1 inhibitorCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 2667US2018119128A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2017·Application pending·0 cites
- 2765US9452203B2Use of C1-inhibitor for the treatment of secondary edema of the central nervous systemCSL BEHRING GMBH·Filed 2012·Granted Sep 27, 2016·1 cites·30 claims
- 2865US9095564B2von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytesCSL BEHRING GMBH·Filed 2013·Granted Aug 4, 2015·1 cites·20 claims
- 2965US7863009B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2008·Granted Jan 4, 2011·0 cites·8 claims
- 3064US7879803B2Methods of treatment involving the protease for activating clotting factor VIICSL BEHRING GMBH·Filed 2007·Granted Feb 1, 2011·0 cites·13 claims
- 3163US7442514B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2004·Granted Oct 28, 2008·0 cites·19 claims
- 3263US2020338123A1Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteinsCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 3361US11426680B2Hydrophobic charge induction chromatographic protein depleted solutionCSL BEHRING GMBH·Filed 2018·Granted Aug 30, 2022·0 cites·12 claims
- 3459US2011189182A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2011·Application pending·0 cites
- 3559US2016010074A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2015·Application pending·0 cites
- 3658US11554156B2Pharmaceutical formulations of C1 esterase inhibitorCSL BEHRING GMBH·Filed 2020·Granted Jan 17, 2023·0 cites·16 claims
- 3757US2014248686A1Therapeutic polypeptides with increased in vivo recoveryCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 3857US2017143805A1Method of purifying therapeutic proteinsCSL BEHRING GMBH·Filed 2017·Application pending·0 cites
- 3956US7803569B2Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutationsCSL BEHRING GMBH·Filed 2006·Granted Sep 28, 2010·0 cites·20 claims
- 4056US2014356346A1MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFECSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 4154US10973891B2Treatment and prevention of remote ischemia-reperfusion injuryCSL BEHRING GMBH·Filed 2019·Granted Apr 13, 2021·0 cites·21 claims
- 4254US2016166660A1Combination therapy using a factor xii inhibitor and a c-1 inhibitorCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 4353US9707269B2Sugar compositions for treating hemophilia A and/or von Willebrand diseaseCSL BEHRING GMBH·Filed 2013·Granted Jul 18, 2017·0 cites·10 claims
- 4453US2014273096A1Modified coagulation factors with prolonged in vivo half-lifeCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 4552US9511123B2Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Dec 6, 2016·0 cites·5 claims
- 4651US10232015B2Sugar compositions for treating hemophilia A and/or Von Willebrand diseaseCSL BEHRING GMBH·Filed 2017·Granted Mar 19, 2019·0 cites·20 claims
- 4751US2024000908A1Method for Treating Antibody-Mediated RejectionCSL BEHRING GMBH·Filed 2021·Application pending·0 cites
- 4850US12065481B2Therapy using a factor XII inhibitor in a neurotraumatic disorderCSL BEHRING GMBH·Filed 2019·Granted Aug 20, 2024·0 cites·18 claims
- 4950US7863006B2Antibodies for specifically detecting pathogenic prions of human origin, and detection methods carried out using these antibodiesCSL BEHRING GMBH·Filed 2007·Granted Jan 4, 2011·0 cites·7 claims
- 5049US9393289B2Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Jul 19, 2016·0 cites·18 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CSL BEHRING GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →